 SAN DIEGO and TOKYO, June 7, 2021 PRNewswire -- MEI Pharma, Inc. NASDAQ: MEIP, a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. Kyowa Kirin, TSE: 4151, a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, today announced the dosing of the first patient with relapsed or refractory marginal zone lymphoma enrolled in the recently added second arm of the global Phase 2 TIDAL study of zandelisib, a selective phosphatidylinositol 3-kinase PI3K delta inhibitor. 